PTPRC and neoplasm: To determine if the enhanced antitumor activity of the combination of anti-PD-1 antibody and HA degradation mediated increased levels of TILs, we collected and analyzed tumor tissues post-treatment using IHC staining with various immune cell markers, including CD45 for leukocytes, CD11b for myeloid cells, and CD3 and CD8 for T cells (Figure 6D).